Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial - Sorbonne Université
Journal Articles European Journal of Cancer Year : 2021

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

Benoît Rousseau
  • Function : Author
Hélène Castanié
  • Function : Author

Domains

Cancer
Fichier principal
Vignette du fichier
S0959804920313137.pdf (550.81 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04548022 , version 1 (29-11-2024)

Licence

Identifiers

Cite

Alice Boilève, Marc Hilmi, Paul Gougis, Romain Cohen, Benoît Rousseau, et al.. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. European Journal of Cancer, 2021, 143, pp.55-63. ⟨10.1016/j.ejca.2020.10.027⟩. ⟨hal-04548022⟩
13 View
0 Download

Altmetric

Share

More